Canine Pipeline

Parvovirus in Dogs


KIND-030 – Parvovirus in dogs

Positive results from pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine parvovirus (CPV)

100% efficacy in prevention of parvovirus infection in prophylactic pivotal study of KIND-030, as well as a mortality benefit in the treated group. We plan to complete remaining pivotal studies on KIND-030 in 2020, and expect approval by early 2021.

Prevalence

CPV is the most significant cause of enteric virus infecting dogs worldwide. Puppies between 10 and 12 weeks of age are particularly vulnerable to CPV because the protective effect of their maternally derived antibodies wanes or there is lack of response to immunization due to maternal antibody interference.¹ Banfield medical records estimate there are approximately 250,000 CPV cases in the United States each year, excluding emergency rooms, shelters, or undiagnosed cases. This does not include the other puppies and dogs that are potentially exposed to the virus.²

Disease Burden

Vaccines are readily available and effectively protect against variants of CPV.³ If approved, KIND-030 would work in conjunction with vaccination protocols and would not replace the need for vaccination. There are currently no approved or unapproved treatments for CPV. Today, management of CPV infection is largely supportive.^3,4

Cost Burden

Hospitalization is generally recommended,⁵ which can be cost prohibitive for some owners.⁶ Within a veterinary practice, treating CPV infection requires implementation of strict isolation and decontamination protocols to minimize spread of the virus, which adds to the cost of treatment.⁷ Despite 40 years of research, there remains a high unmet medical need for an effective targeted therapeutic for CPV.

Near-term Catalysts

Completion of remaining pivotal studies for this molecule are expected by year-end 2020, with approval anticipated by early 2021.

References:

1. Altman KD, Kelman M, Ward MP. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure? Vet Microbiol. 2017; 210:8-16.
2. Banfield Pet Hospital. State of Pet Health Report(tm) 2014. Available at: https://www.banfield.com/Banfield/media/PDF/Downloads/soph/Banfield-State-of-Pet-Health-Report_2014.pdf [Access date: March 17, 2020].
3. Wilson S, Illambas J, Siedek E, et al. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c. Vaccine. 2014;32(42):5420-5424.
4. Greene CE, Decaro N. Canine viral enteritis. In: Green CE, ed. Infectious Diseases of the Dog and Cat, 4th ed. St. Louis, MO: Elsevier Saunders; 2012:67-80.
5. Venn EC, Preisner K, Boscan PL, et al. Evaluation of an outpatient protocol in the treatment of canine parvoviral enteritis. J Vet Emerg Crit Care (San Antonio). 2017;27(1):52-65.
6. Kelman M, Ward MP, Barrs VR, Norris JM. The geographic distribution and financial impact of canine parvovirus in Australia. Transbound Emerg Dis. 2019;66(1):299-311.
7. Nandi S, Kumar M. Canine parvovirus: current perspective. Indian J Virol. 2010;21(1):31-44.

US-CORP-2000022 MAR-20